Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
Shattuck Labs (STTK) Stock Price & Analysis
166 Followers
STTK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.33 - $11.76
Previous Close$7.02
Volume385.94K
Average Volume (3M)313.17K
Market Cap
$333.81M
Enterprise Value$206.59M
Total Cash (Recent Filing)$130.63M
Total Debt (Recent Filing)$3.41M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Aug 08, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding47,550,872
10 Day Avg. Volume162,089
30 Day Avg. Volume313,173
Standard Deviation0.48
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.31
Price to Sales (P/S)201.45
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue124.68
Enterprise Value/Gross Profit124.68
Enterprise Value/Ebitda-3.54
Forecast
1Y Price Target
$15.00Price Target Upside123.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Shattuck Labs News
PremiumPress Releases
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
PremiumPress Releases
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentShattuck’s SL-172154 remains undeterred in its CD47 development plans, highlighting a key window of opportunity to distinguish itself in the competitive landscape.
Financial HealthShattuck's solid financial position, with sufficient cash to support operations into 2026, provides a stable foundation for continued development and upcoming clinical trial readouts.
Therapeutic PotentialUpdated Phase 1b data for SL-172154 suggest encouraging interim efficacy and safety, with a high objective response rate and sustained benefits, indicating strong clinical performance in a difficult to treat patient population.
Bears Say
Clinical Trial OutcomesLanguishing clinical studies and disappointing safety results in the CD47 landscape could negatively impact investor confidence in biotech stocks.
Drug EfficacyLower CR+CRi rates in AML data may raise concerns about the efficacy of treatments, potentially affecting the stock's appeal to investors.
Financial HealthSTTK's reported Q4 net loss could reflect poorly on the company’s financial stability, possibly leading to a decline in stock value.
---
Ownership Overview
26.29% Insiders
18.60% Mutual Funds
35.68% Other Institutional Investors
19.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $1.33 and its highest was $11.76 in the past 12 months.
What is Shattuck Labs’s market cap?
Currently, no data Available
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is Aug 08, 2024 which is in 58 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on May 02, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.448 by $0.078.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -$0.41.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 47,550,873 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.448. Following the earnings report the stock price went up 2.21%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
---
Shattuck Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (123.88% Upside)
$15.00 (123.88% Upside)
Blogger Sentiment
Bullish
STTK Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $10.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.16%
12-Months-Change
Fundamentals
Return on Equity
-59.40%
Trailing 12-Months
Asset Growth
-17.64%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company's product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
---
STTK Earnings Call
Q3 2023
0:00 / 0:00
---
STTK Stock 12 Month Forecast
Average Price Target
$15.00
▲(123.88% Upside)
Technical Analysis
Best Analysts Covering STTK
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+111.94%
reiterated a buy rating 27 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +111.94% per trade.
---